Strategic Report on Non-Radiographic Axial Spondyloarthritis Therapeutic Market: Growth Opportunities and Emerging Challenges
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Non-Radiographic Axial Spondyloarthritis Therapeutic Industry?
The therapeutic market for non-radiographic axial spondyloarthritis has experienced swift expansion in recent times. Projected growth sees it rising from $0.93 billion in 2024 to $1.04 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 10.9%. This growth in the past period can be linked to several factors: dynamic growing prevalence of axial spondyloarthritis, the expansion of patient pool due to heightened awareness, the rise in disease consciousness promoting market growth, accelerated research and developmental projects, along with an augmenting adoption of biologic therapies.
In the coming years, the non-radiographic axial spondyloarthritis therapeutic market is projected to experience significant growth, with its market size escalating to $1.55 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. This growth during the forecast period can be associated with factors such as increased awareness and early determination, the proliferation of biosimilars, continuous progress in biologics and availability of new therapeutic alternatives in the pipeline. Other factors include aggressive research and development efforts, the growing preference for targeted and personalized treatments, and the advancement of healthcare infrastructure. Critical trends for the forecast period include the utilization of personalised treatment patterns, the incorporation of digital tools in diagnosis, a shift towards treat-to-target (T2T) strategies, value-driven pricing models, and the uptake of multidisciplinary management approaches.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24627&type=smp
#Which Factors Are Currently Driving The Growth Of The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
The escalating number of clinical trials is predicted to fuel the expansion of the non-radiographic axial spondyloarthritis therapeutic market in the future. Clinical trials, which are research studies performed on humans to assess the safety, effectiveness, and side effects of medical treatments, are on the rise due to the burgeoning demand for innovative and personalized treatments that necessitate meticulous testing for safety and efficacy. These clinical trials are instrumental to non-radiographic axial spondyloarthritis therapeutics since they offer evidence-based confirmation of treatment effectiveness and safety at the early stages of the disease, thus influencing regulatory approvals and clinical application. For example, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported a 15% annual increase in recruitment for industry clinical trials in the UK, with the numbers jumping from 36,722 participants in 2021-22 to 42,088 in 2022-23. As a result, the upsurge in clinical trials is bolstering the growth of the non-radiographic axial spondyloarthritis therapeutic market.
How Is The Global Non-Radiographic Axial Spondyloarthritis Therapeutic Market Structured In Terms Of Segments?
The non-radiographic axial spondyloarthritis therapeutic market covered in this report is segmented –
1) By Type: Non-Steroidal Anti-Inflammatory Drugs, Biologics, Small Molecule Therapies, Corticosteroids
2) By Application: Oral, Injectable, Topical
3) By End User: Hospitals, Ambulatory Surgical Centers, Homecare Settings
Subsegments:
1) By Non-Steroidal Anti-Inflammatory Drugs: COX-2 Inhibitors, Non-Selective NSAIDs
2) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-17 (IL-17) Inhibitors
3) By Small Molecule Therapies: Janus Kinase (JAK) Inhibitors, Phosphodiesterase-4 (PDE4) Inhibitors
4) By Corticosteroids: Oral Corticosteroids, Intra-Articular Corticosteroid Injections
What Trends Are Currently Influencing Growth In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
Key players in the non-radiographic axial spondyloarthritis (nr-axSpA) treatment market are striving to secure regulatory permissions to extend their market presence, quicken the release of new therapies, and achieve a competitive edge. These regulatory consents are an official approval given by government entities, allowing a medication or therapy to be legally sold and prescribed after demonstrating its safety, effectiveness, and adherence to applicable criteria. For example, in October 2022, AbbVie Inc., a biopharmaceutical company based in the United States, attained FDA approval for their drug Rinvoq (upadacitinib) for the treatment of adults with active nr-axSpA who show clear signs of inflammation and whose condition hasn’t adequately responded to TNF inhibitors. This approval represents the sixth U.S. certification for Rinvoq, positioning it as the first and only oral JAK inhibitor approved for nr-axSpA. The sanction is built on the results from the SELECT-AXIS 2 clinical trial, in which nearly fifty percent of the patients treated with Rinvoq experienced a substantial reduction in disease activity compared to the placebo at 14 weeks, thereby providing a new daily oral treatment alternative for those dealing with this difficult disease.
Who Are The Main Participants Shaping The Non-Radiographic Axial Spondyloarthritis Therapeutic Market Landscape?
Major companies operating in the non-radiographic axial spondyloarthritis therapeutic market are Pfizer Inc., Johnson & Johnson, Allergan plc, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Mochida Pharmaceutical Co. Ltd., Mereo BioPharma Group plc, Suzhou Zelgen Biopharmaceuticals Co. Ltd., Qyuns Therapeutics Co. Ltd.
Get The Full Report Here:
Which Region Currently Holds The Largest Share In The Non-Radiographic Axial Spondyloarthritis Therapeutic Market?
North America was the largest region in the non-radiographic axial spondyloarthritis therapeutics market in 2024. The regions covered in the non-radiographic axial spondyloarthritis therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24627&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
